GlassScriptPhysician profile
Kelly Le
NPI 1871099820
$1,782.09
in general payments reported to CMS, 2019-2025
15 companies · $783 in 2025
The $783 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.58 · 2024: $980 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,782.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $336.68 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $268.91 | 2023-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $225.90 | 2024 | |
| Xeris Pharmaceuticals, INC. | $206.56 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $181.59 | 2024-2025 | Korlym |
| Radius Health, INC. | $134.32 | 2024-2025 | Tymlos |
| Abbvie INC. | $89.59 | 2024-2025 | |
| Dexcom, INC. | $77.76 | 2024-2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $76.48 | 2024-2025 | Unithroid |
| Alexion Pharmaceuticals, INC. | $60.24 | 2024-2025 | Strensiq |
| Cequr Corporation | $42.08 | 2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.13 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $19.88 | 2025 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $15.00 | 2025 | Isturisa |
| Medtronic, INC. | $14.97 | 2024 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.